Licensing Opportunities with PyroTIMER

Pyrojas offers licensing opportunities for its groundbreaking PyroTIMER platform, a universal CAR-T/TCR-T enhancement technology designed to overcome immunosuppressive tumor microenvironments (TIME) and significantly improve T cell persistence, cytotoxicity, and durability. Our licensing model allows cell therapy companies, CDMOs, and CROs to integrate PyroTIMER seamlessly into their pipelines—providing differentiation, competitive advantage, and faster clinical validation.

​

Interested in integrating PyroTIMER into your CAR-T/TCR-T pipeline?
Contact us to explore partnership opportunities